Back to top
more

BioScrip, Inc. (BIOS)

(Delayed Data from NSDQ)

$1.98 USD

1.98
1,268,889

+0.05 (2.59%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.98 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Option Care (BIOS) Down 12% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Option Care (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Option Care Health (BIOS) Surges: Stock Moves 7.3% Higher

by Zacks Equity Research

Option Care Health (BIOS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Option Care is the Preferred Provider of Haemophilia Treatment

by Zacks Equity Research

Option Care Health (BIOS) can currently access all hemophilia factor treatments.

Option Care Health (BIOS) Q3 Earnings Meet, Revenues Top

by Zacks Equity Research

Albeit Option Care Health (BIOS) is yet to reap material benefits from its merger-related synergies, the reporting of a positive gross margin in third-quarter results is encouraging for investors.

Option Care (BIOS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Option Care (BIOS) delivered earnings and revenue surprises of 0.00% and 17.94%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Option Care (BIOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Option Care (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Benjamin Rains headshot

Learn How to Find Top-Ranked 'Cheap' Stocks Under $10 with this Screener

by Benjamin Rains

Searching for 'cheap' stocks that look poised to climb can be an attractive investment strategy. But investors have to know where and how to find strong stocks trading under $10 a share. So check out this Zacks Stock Screener...

Here's Why Momentum Investors Will Love BioScrip (BIOS)

by Zacks Equity Research

Does BioScrip (BIOS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Moving Average Crossover Alert: Option Care Health

by Zacks Equity Research

Option Care Health is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Top Ranked Momentum Stocks to Buy for September 12th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 12th

BioScrip Closes Option Care Merger, Incurs Wider Q2 Loss

by Zacks Equity Research

With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.

BioScrip (BIOS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioScrip (BIOS) delivered earnings and revenue surprises of -30.00% and 3.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

BioScrip, Inc. (BIOS) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in BioScrip, Inc. (BIOS).

BioScrip, Inc.'s Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in BioScrip.

BioScrip (BIOS) Up 5.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioScrip's Option Care Merger on Track, Q1 Loss Narrows

by Zacks Equity Research

BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.

BioScrip (BIOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

BioScrip (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioScrip (BIOS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioScrip (BIOS) delivered earnings and revenue surprises of 16.67% and 0.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Moving Average Crossover Alert: BioScrip

by Zacks Equity Research

BioScrip, Inc. (BIOS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

    Why Is BioScrip (BIOS) Down 50.4% Since Last Earnings Report?

    by Zacks Equity Research

    BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    New Strong Sell Stocks for April 11th

    by Zacks Equity Research

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

    New Strong Sell Stocks for April 9th

    by Zacks Equity Research

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

    New Strong Sell Stocks for April 1st

    by Zacks Equity Research

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

    BioScrip (BIOS) Reports Loss in Q4, Both Margins Contract

    by Zacks Equity Research

    The combined expertise of BioScrip (BIOS) and OptionCare is expected to drive significant growth for the former.

    Do Options Traders Know Something About BioScrip (BIOS) Stock We Don't?

    by Zacks Equity Research

    Investors need to pay close attention to BioScrip (BIOS) stock based on the movements in the options market lately.